Nanotechnology-Driven Drug Delivery in Rheumatoid Arthritis: Current Trends, Key Challenges, and Future Perspectives

Minal Raghunath Narkhede^* and Shruti Nanaji Bhamare

Department of Pharmaceutics, Smbt College of Pharmacy, Savitribai Phule Pune University,  Maharashtra, India.

Corresponding Author E-mail:smbt_pharmaceutics@rediffmail.com

ABSTRACT: Rheumatoid arthritis is a chronic autoimmune disorder that causes progressive joint damage and disability, significantly impacting patients' quality of life. In this Rheumatoid arthritis Traditional treatment, including disease-modifying ant rheumatic drugs and biologics often fall short in targeting the disease with precision, leading to side effects and limited efficacy. We selected Nanotechnology which offers a promising solution for improving drug delivery and enhancing therapeutic outcomes in RA management. This review explores the current trends and future prospects of nanotechnology-based drug delivery systems in Rheumatoid arthritis treatment. We discuss various types of nanocarriers, such as nanoparticles, liposomes, and micelles, and their ability to enhance the targeted delivery of biologic agents and small molecules. Additionally, we examine the potential of "smart" nanomaterials that respond to disease-specific stimuli for controlled release, thereby reducing systemic toxicity. The integration of nanotechnology with biologics, gene therapies, and combination treatments is highlighted as a promising strategy for improving efficacy and minimizing adverse effects. Finally, this review addresses ongoing challenges and future directions, including the need for more extensive clinical trials to ensure the safety and effectiveness of these innovative therapies in RA patients.

KEYWORDS: Drug Delivery; Nano carriers; Nanotechnology; Rheumatoid Arthritis; Smart Nanomaterials; Targeted Therapeutics

[ HTML Full Text]